L&K Biomed said on Monday it obtained FDA approval for PathLoc-TM, a next-generation height-expandable spinal implant product for the treatment of spinal diseases.

PathLoc-TM is used in the posterior and posterolateral positions, where the procedure is most frequently performed in spinal implants.

According to L&K Biomed, the expandable interbody cage can be inserted with a minimum height, allowing minimally invasive surgery with a minimum incision. In addition, this feature raises patient satisfaction after surgery, the company said.

PathLoc-TM comes in an H shape to fill more bone graft materials than existing products, which improves bone fusion. In addition, depending on the patient’s spine positions, the angle of insertion (up to 20 degrees), the length (up to 25 mm), and the height (up to 4 mm) can be extended, the company added.

“PathLoc-TM showcases L&J Biomed’s exclusive technology. As a result, it can secure the global spinal implant market, which grew to 9 trillion won ($7.2 billion) due to the increase of the elderly population and obesity-related diseases,” an official at L&K Biomed said.

The official added that with the FDA nod, the company would secure a market share through direct sales in the U.S. through a U.S. branch established in the first half of the year.

“This will help increase the company’s revenue and promote our brand,” she said.